Bladder Cancer Clinical Trial

Evaluation of a Patient-Reported Symptom Index for NMIBC

Summary

This project will develop and evaluate a patient-reported symptom index to assess the impact of treatment for non-muscle invasive bladder cancer on patient burden, toxicity, symptoms and side effects. The symptom index will provide a method for assessing treatments from the patient's perspective; help healthcare professionals make better informed treatment decisions, and provide a method to be able to effectively evaluate treatments for non-muscle invasive bladder cancer.

View Full Description

Full Description

The overarching aim of this research is to develop and evaluate a patient-reported Symptom Index (SI) for individuals with NMIBC (the NMIBC-SI) that is acceptable to patients, reliable, valid and responsive, and fit for purpose in clinical trials and clinical practice.

Specific clinical aims:

Assess and compare key Patient-Reported Outcomes (PROs) across the full range of contemporary treatments for NMIBC, and over the disease trajectory including acute treatment and 1year survivorship;
Compare PROs between patients with low, intermediate, and high risk NMIBC.

In field test 1, 200 participants will complete one questionnaire either in hard copy (pencil and paper) or online, at a time that is convenient for the participant. The questionnaire may take up to 20 minutes to complete.

In field test 2, 250 participants will complete quality of life questionnaires at four different time points; 1) before tumour resection, 2) 1 week after resection, 3) 8 weeks after resection, and 4) 1 year after resection. The questionnaires can be completed in the clinic or at home, either in hard copy (pencil and paper) or online, at a time that is convenient for the participant but still within the relevant time point. The questionnaires may take up to 30 minutes to complete.

View Eligibility Criteria

Eligibility Criteria

Field test 1:

Inclusion Criteria:

diagnosed NMIBC
Adult (>18yrs)
able to read and understand English
undergoing active treatment (i.e. one week after tumour resection or intravesical therapy) or completed final treatment for NMIBC within the last week

Exclusion Criteria:

unconscious or confused
have cognitive impairment
unable to speak, read and/or write in English
diagnosed with muscle invasive disease
unable to provide informed consent

Field test 2:

Inclusion Criteria:

newly diagnosed NMIBC
Adult (>18yrs)
able to read and understand English
after imaging or flexible cystoscopy, and before active treatment
either before endoscopic resection, or more than 4 weeks since endoscopic resection, but before active/ongoing treatment

Exclusion Criteria:

unconscious or confused
have cognitive impairment
unable to speak, read and/or write in English
diagnosed with muscle invasive disease
unable to provide informed consent
currently undergoing active treatment for any bladder cancer, or finished treatment within last 3 years.

Study is for people with:

Bladder Cancer

Estimated Enrollment:

498

Study ID:

NCT03091764

Recruitment Status:

Completed

Sponsor:

University of Sydney

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 17 Locations for this study

See Locations Near You

University of Kansas
Kansas City Kansas, 66160, United States
University of Minnesota
Minneapolis Minnesota, 55455, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Concord Hospital
Concord New South Wales, 2139, Australia
Royal North Shore Hospital
St Leonards New South Wales, 2065, Australia
Riverina Cancer Care Centre
Wagga Wagga New South Wales, 2650, Australia
The Urological Cancer Centre, Westmead Specialist Centre
Westmead New South Wales, 2145, Australia
Westmead Hospital
Westmead New South Wales, 2145, Australia
Mater Misericordiae Limited
South Brisbane Queensland, 4101, Australia
Box Hill Hospital
Box Hill Victoria, 3128, Australia
Austin Health
Heidelberg Victoria, 3084, Australia
Alfred Health
Melbourne Victoria, 3004, Australia
Monash Health
Moorabbin Victoria, 3189, Australia
Royal Melbourne Hospital
Parkville Victoria, 3052, Australia
Fiona Stanley Hospital
Murdoch Western Australia, 6150, Australia
University of British Columbia
Vancouver British Columbia, , Canada
Canterbury Urology Research Trust
Christchurch , 8013, New Zealand
Tauranga Urology Research
Tauranga , 3140, New Zealand
Salford Royal NHS Foundation Trust
Salford Manchester, M5 5A, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Estimated Enrollment:

498

Study ID:

NCT03091764

Recruitment Status:

Completed

Sponsor:


University of Sydney

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider